GlobeNewswire Inc | Sep 29, 2021 08:06AM EDT

September 29, 2021

BOTHELL, Wash., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that updates and baseline data from two ongoing Phase 2 and Phase 2/3 clinical trials of its lead development candidate ATH-1017, a novel small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor MET, in mild-to-moderate Alzheimers disease, will be presented as an oral presentation at the upcoming 2021 Clinical Trials on Alzheimers Disease (CTAD) conference taking place Nov. 9-12, 2021 both virtually and in-person in Boston.

Oral Presentation Details:Title: Phase 2/3 trials of ATH-1017, a novel treatment for mild-to-moderate Alzheimer's disease: Updates and baseline dataPresentation Number: OC10Presenter: Hans Moebius, M.D., Ph.D., Chief Medical Officer, Athira PharmaDate: Wednesday, Nov. 10, 2021Time: 1:55 p.m. ET

About Athira Pharma, Inc.Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimers and Parkinsons dementia. For more information, visitwww.athira.com. You can also follow Athira onFacebook,LinkedInand@athirapharma onTwitterandInstagram.

Investor & Media ContactJulie RathbunJulie.rathbun@athira.com206-769-9219